Treatment of Acute Otitis Media in Adults
For otherwise healthy adults with acute otitis media, amoxicillin is the recommended first-line antibiotic therapy, though observation with symptomatic treatment alone is a reasonable alternative for those with non-severe symptoms and assured follow-up.
Diagnostic Confirmation
Before initiating treatment, confirm the diagnosis requires all three elements 1:
- Acute onset of signs and symptoms (otalgia, fever, otorrhea)
- Presence of middle ear effusion (bulging tympanic membrane, limited/absent mobility, air-fluid level, or otorrhea)
- Signs of middle ear inflammation (distinct erythema of tympanic membrane)
Use pneumatic otoscopy to assess tympanic membrane mobility—this is critical for distinguishing acute otitis media from otitis media with effusion, which does not require antibiotics 1.
Pain Management (Priority)
Address pain immediately, regardless of whether antibiotics are prescribed 1. This is a strong recommendation based on randomized trials. Pain management during the first 24 hours is essential and should not be viewed as peripheral to treatment.
Treatment Algorithm
Option 1: Observation (Watchful Waiting)
Appropriate for adults with:
- Non-severe symptoms (no high fever, no intense otalgia)
- Uncertain diagnosis
- Assured follow-up within 48-72 hours 1
Provide symptomatic relief only and reassess at 48-72 hours. Many cases resolve spontaneously.
Option 2: Immediate Antibiotic Therapy
First-line antibiotic: Amoxicillin 1, 2
The bacteriology in adults mirrors that of children: Streptococcus pneumoniae (21%) and Haemophilus influenzae (26%) are the primary pathogens 2. Amoxicillin provides:
- Effective coverage against susceptible and intermediate-resistant pneumococci
- Good activity against H. influenzae (though 22% produce beta-lactamase) 2
- Safety, low cost, and narrow spectrum
Dosing for adults: Standard adult dosing (typically 500 mg three times daily or 875 mg twice daily). While pediatric guidelines specify 80-90 mg/kg/day 1, adult dosing follows standard protocols.
Duration: 5-10 days (guidelines vary; 5 days may be sufficient for adults based on extrapolation from pediatric data) 1, 3.
Second-line Options (if amoxicillin fails or beta-lactam allergy)
For treatment failure at 48-72 hours 1:
- Amoxicillin-clavulanate (covers beta-lactamase producers) 4, 3
- Cefuroxime axetil 4, 3, 2
- Cefpodoxime proxetil 4, 3
- Cefdinir 1, 4
For beta-lactam allergy 1:
- Macrolides (azithromycin, clarithromycin) have 20-25% bacterial failure rates 4
- Fluoroquinolones (levofloxacin, moxifloxacin) for moderate disease 4
Antibiotics to Avoid
Do NOT use as first-line 2, 5:
- Penicillin V (inactive against H. influenzae)
- Cephalexin (inadequate H. influenzae coverage)
- Erythromycin alone (poor H. influenzae coverage)
- Tetracyclines (inadequate coverage)
Reassessment Protocol
If no improvement by 48-72 hours 1:
- Confirm the diagnosis is truly acute otitis media (not otitis externa or other pathology)
- Exclude other causes of illness
- If initially observed without antibiotics → start amoxicillin
- If initially treated with amoxicillin → switch to amoxicillin-clavulanate or second-generation cephalosporin
Common Pitfalls
- Mistaking otitis media with effusion for acute otitis media: The former does not require antibiotics 1. Ensure all three diagnostic criteria are met.
- Prescribing topical antibiotics: Recent data shows 21% of adults receive topical antibiotics for AOM 6, which is inappropriate—topical therapy is for otitis externa, not otitis media.
- Overprescribing oral antibiotics: Current prescription rates are 46% in adults 6, but observation is appropriate for many cases.
- Using broad-spectrum agents unnecessarily: Reserve fluoroquinolones for treatment failures to minimize resistance 4.
Evidence Quality Note
The available guidelines 1 are from 2004 and focus primarily on pediatric populations. However, adult bacteriology studies 2 confirm similar pathogens, validating the extrapolation of treatment recommendations. Recent epidemiologic data 6 shows stable AOM incidence in adults (5.3/1000 person-years), with higher rates in younger adults and those with atopy.